Knockdown of c-mip prevents the development of nephrotic proteinuria. (A) Detection of c-mip in LPS-treated Balb/c mice. Immunohistochemistry analysis showing a greater abundance of c-mip in podocytes (upper panel). Scale bars, 20 μM. Immunoprecipitation of glomerular extracts from LPS treated mice with anti-Fyn or mouse IgG (lower panel). (B) Increased abundance of c-mip in the podocytes of LPS-treated SCID mice than in those of untreated SCID mice. Scale bars, 20 μM. (C) Effects of c-mip siRNA injection in LPS-treated Balb/c mice. Balb/c mice (n=10 mice) received a single injection of c-mip siRNA (10 mg/kg) coupled to Alexa Fluor 647 into the internal jugular vein, and after 30 min, were injected intraperitoneally with LPS (200 μg). Controls include mice injected with LPS (n=5 mice) or Invivofectamine (n=5 mice) and non-injected mice (NI, n=5 mice). Urine was collected over a 24-hour period and the kidneys were harvested and processed for immunohistochemistry. Alexa Fluor 647 staining of kidney sections demonstrated that c-mip-siRNA duplexes were delivered to podocytes (upper panel). Scale bars, 10 μM. Immunohistochemistry analysis showed that mice treated with LPS and c-mip siRNA contained less c-mip than mice treated with LPS only (middle panel). Scale bars, 10 μM. RT-qPCR analysis of c-mip expression in mouse kidney (lower panel, left). mRNA abundance is expressed with respect to glyceraldehyde-3-phosphate deshydrogenase (GAPDH). Data are means ± SEM (p<0.05, Kruskal-Wallis test). Proteinuria was significantly lower in c-mip siRNA-treated mice than in mice treated with LPS alone (p=0.0017, Kruskal-Wallis test) (lower panel, left).